Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Cell

Volumn 171, Issue 3, 2017, Pages 696-709.e23

  Bar Peled, Liron ^a   Kemper, Esther K ^a   Suciu, Radu M ^a   Vinogradova, Ekaterina V ^a   Backus, Keriann M ^a   Horning, Benjamin D ^a   Paul, Thomas A ^b   Ichu, Taka Aki ^a   Svensson, Robert U ^c   Olucha, Jose ^a   Chang, Max W ^d   Kok, Bernard P ^a   Zhu, Zhou ^b   Ihle, Nathan T ^b   Dix, Melissa M ^a   Jiang, Ping ^b   Hayward, Matthew M ^b   Saez, Enrique ^a   Shaw, Reuben J ^c   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

activity based profiling; chemical proteomics; covalent; fragment; KEAP1; lung cancer; mass spectrometry; NR0B1; NRF2

Indexed keywords

CYSTEINE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NUCLEAR RECEPTOR DAX 1; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; LIGAND; NR0B1 PROTEIN, HUMAN; PROTEOME; TRANSCRIPTOME;

A-549 CELL LINE; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; COMPLEX FORMATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; H2122 CELL LINE; HEK293T CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NCI-H1792 CELL LINE; NCI-H1975 CELL LINE; NCI-H2009 CELL LINE; NCI-H358 CELL LINE; NCI-H460 CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; TRANSCRIPTION REGULATION; CHEMISTRY; GENE REGULATORY NETWORK; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYSTEINE; DAX-1 ORPHAN NUCLEAR RECEPTOR; GENE REGULATORY NETWORKS; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LIGANDS; LUNG NEOPLASMS; PROTEOME; TRANSCRIPTOME;

EID: 85030717636     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.08.051     Document Type: Article

References (56)

1. Albers, M., Kranz, H., Kober, I., Kaiser, C., Klink, M., Suckow, J., Kern, R., Koegl, M., Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol. Cell. Proteomics 4 (2005), 205–213.
2. Ashouri, A., Sayin, V.I., Van den Eynden, J., Singh, S.X., Papagiannakopoulos, T., Larsson, E., Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events. Nat. Commun., 0, 2016, 13197.
3. Backus, K.M., Correia, B.E., Lum, K.M., Forli, S., Horning, B.D., González-Páez, G.E., Chatterjee, S., Lanning, B.R., Teijaro, J.R., Olson, A.J., et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534 (2016), 570–574.
4. Bar-Peled, L., Chantranupong, L., Cherniack, A.D., Chen, W.W., Ottina, K.A., Grabiner, B.C., Spear, E.D., Carter, S.L., Meyerson, M., Sabatini, D.M., A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340 (2013), 1100–1106.
5. Berger, A.H., Brooks, A.N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30 (2016), 214–228.
6. Bollong, M.J., Yun, H., Sherwood, L., Woods, A.K., Lairson, L.L., Schultz, P.G., A small molecule inhibits deregulated Nrf2 transcriptional activity in cancer. ACS Chem. Biol. 10 (2015), 2193–2198.
7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
8. Chio, I.I., Jafarnejad, S.M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. Nrf2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166 (2016), 963–976.
9. Chung, H.S., Wang, S.B., Venkatraman, V., Murray, C.I., Van Eyk, J.E., Cysteine oxidative posttranslational modifications: emerging regulation in the cardiovascular system. Circ. Res. 112 (2013), 382–392.
10. Dickinson, B.C., Peltier, J., Stone, D., Schaffer, D.V., Chang, C.J., Nox2 redox signaling maintains essential cell populations in the brain. Nat. Chem. Biol. 7 (2011), 106–112.
11. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
12. Ehrlund, A., Anthonisen, E.H., Gustafsson, N., Venteclef, N., Robertson Remen, K., Damdimopoulos, A.E., Galeeva, A., Pelto-Huikko, M., Lalli, E., Steffensen, K.R., et al. E3 ubiquitin ligase RNF31 cooperates with DAX-1 in transcriptional repression of steroidogenesis. Mol. Cell. Biol. 29 (2009), 2230–2242.
13. Finlay, M.R., Anderton, M., Ashton, S., Ballard, P., Bethel, P.A., Box, M.R., Bradbury, R.H., Brown, S.J., Butterworth, S., Campbell, A., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57 (2014), 8249–8267.
14. García-Aragoncillo, E., Carrillo, J., Lalli, E., Agra, N., Gómez-López, G., Pestaña, A., Alonso, J., DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 27 (2008), 6034–6043.
15. Giles, N.M., Giles, G.I., Jacob, C., Multiple roles of cysteine in biocatalysis. Biochem. Biophys. Res. Commun. 300 (2003), 1–4.
16. Goldstein, L.D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C.E., Holcomb, T., Shames, D.S., et al. Recurrent loss of NFE2L2 exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep. 16 (2016), 2605–2617.
17. Goodwin, J.M., Svensson, R.U., Lou, H.J., Winslow, M.M., Turk, B.E., Shaw, R.J., An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol. Cell 55 (2014), 436–450.
18. Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12 (2013), 931–947.
19. Huang da, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
20. Iyer, A.K., McCabe, E.R., Molecular mechanisms of DAX1 action. Mol. Genet. Metab. 83 (2004), 60–73.
21. Johnson, D.S., Weerapana, E., Cravatt, B.F., Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2 (2010), 949–964.
22. Kinsey, M., Smith, R., Iyer, A.K., McCabe, E.R., Lessnick, S.L., EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res. 69 (2009), 9047–9055.
23. Klijn, C., Durinck, S., Stawiski, E.W., Haverty, P.M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33 (2015), 306–312.
24. Komashko, V.M., Acevedo, L.G., Squazzo, S.L., Iyengar, S.S., Rabinovich, A., O'Geen, H., Green, R., Farnham, P.J., Using ChIP-chip technology to reveal common principles of transcriptional repression in normal and cancer cells. Genome Res. 18 (2008), 521–532.
25. Lamia, K.A., Sachdeva, U.M., DiTacchio, L., Williams, E.C., Alvarez, J.G., Egan, D.F., Vasquez, D.S., Juguilon, H., Panda, S., Shaw, R.J., et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science 326 (2009), 437–440.
26. Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9 (2012), 357–359.
27. Lee, J.G., Baek, K., Soetandyo, N., Ye, Y., Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. Nat. Commun., 4, 2013, 1568.
28. Leinonen, H.M., Kansanen, E., Pölönen, P., Heinäniemi, M., Levonen, A.L., Role of the Keap1-Nrf2 pathway in cancer. Adv. Cancer Res. 122 (2014), 281–320.
29. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S.J., Jones, L.H., Gray, N.S., Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20 (2013), 146–159.
30. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
31. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., Motohashi, H., Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79.
32. Niphakis, M.J., Lum, K.M., Cognetta, A.B. 3rd, Correia, B.E., Ichu, T.A., Olucha, J., Brown, S.J., Kundu, S., Piscitelli, F., Rosen, H., Cravatt, B.F., A global map of lipid-binding proteins and their ligandability in cells. Cell 161 (2015), 1668–1680.
33. Oda, T., Tian, T., Inoue, M., Ikeda, J., Qiu, Y., Okumura, M., Aozasa, K., Morii, E., Tumorigenic role of orphan nuclear receptor NR0B1 in lung adenocarcinoma. Am. J. Pathol. 175 (2009), 1235–1245.
34. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., Shokat, K.M., K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503 (2013), 548–551.
35. Pace, N.J., Weerapana, E., Zinc-binding cysteines: diverse functions and structural motifs. Biomolecules 4 (2014), 419–434.
36. Pan, Z., Bruton's tyrosine kinase as a drug discovery target. Drug News Perspect. 21 (2008), 357–362.
37. Planken, S., Behenna, D.C., Nair, S.K., Johnson, T.O., Nagata, A., Almaden, C., Bailey, S., Ballard, T.E., Bernier, L., Cheng, H., et al. Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR. J. Med. Chem. 60 (2017), 3002–3019.
38. Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476 (2011), 346–350.
39. Rostovtsev, V.V., Green, L.G., Fokin, V.V., Sharpless, K.B., A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl. 41 (2002), 2596–2599.
40. Sablin, E.P., Woods, A., Krylova, I.N., Hwang, P., Ingraham, H.A., Fletterick, R.J., The structure of corepressor Dax-1 bound to its target nuclear receptor LRH-1. Proc. Natl. Acad. Sci. USA 105 (2008), 18390–18395.
41. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P., Sabatini, D.M., Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004), 1296–1302.
42. Schafer, Z.T., Grassian, A.R., Song, L., Jiang, Z., Gerhart-Hines, Z., Irie, H.Y., Gao, S., Puigserver, P., Brugge, J.S., Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461 (2009), 109–113.
43. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelson, T., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., Zhang, F., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 (2014), 84–87.
44. Shestov, A.A., Liu, X., Ser, Z., Cluntun, A.A., Hung, Y.P., Huang, L., Kim, D., Le, A., Yellen, G., Albeck, J.G., Locasale, J.W., Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. eLife, 3, 2014, e03342.
45. Singh, A., Venkannagari, S., Oh, K.H., Zhang, Y.-Q., Rohde, J.M., Liu, L., Ninmagadda, S., Sudini, K., Brimacombe, K.R., Gajghate, S., et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 11 (2016), 3214–3225.
46. Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12 (2012), 564–571.
47. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
48. Suntharalingham, J.P., Buonocore, F., Duncan, A.J., Achermann, J.C., DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best Pract. Res. Clin. Endocrinol. Metab. 29 (2015), 607–619.
49. Thorarensen, A., Dowty, M.E., Banker, M.E., Juba, B., Jussif, J., Lin, T., Vincent, F., Czerwinski, R.M., Casimiro-Garcia, A., Unwalla, R., et al. Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J. Med. Chem. 60 (2017), 1971–1993.
50. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
51. Wang, C., Yan, R., Luo, D., Watabe, K., Liao, D.F., Cao, D., Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 284 (2009), 26742–26748.
52. Weerapana, E., Speers, A.E., Cravatt, B.F., Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)-a general method for mapping sites of probe modification in proteomes. Nat. Protoc. 2 (2007), 1414–1425.
53. Weerapana, E., Wang, C., Simon, G.M., Richter, F., Khare, S., Dillon, M.B., Bachovchin, D.A., Mowen, K., Baker, D., Cravatt, B.F., Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468 (2010), 790–795.
54. Yang, J., Gupta, V., Carroll, K.S., Liebler, D.C., Site-specific mapping and quantification of protein S-sulphenylation in cells. Nat. Commun., 5, 2014, 4776.
55. Yun, J., Mullarky, E., Lu, C., Bosch, K.N., Kavalier, A., Rivera, K., Roper, J., Chio, I.I., Giannopoulou, E.G., Rago, C., et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350 (2015), 1391–1396.
56. Zhang, C., Dowd, D.R., Staal, A., Gu, C., Lian, J.B., van Wijnen, A.J., Stein, G.S., MacDonald, P.N., Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J. Biol. Chem. 278 (2003), 35325–35336.